- Home
- GERN vs SLS Comparison
GERN vs SLS Comparison
Compare GERN & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | SLS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | 258 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 808.3M | 924.5M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | GERN | SLS |
|---|---|---|
| Price | $1.26 | $9.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.17 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 13.9M | 8.7M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.04 | $1.39 |
| 52 Week High | $2.01 | $9.24 |
Technical Indicators
Market Signals| Indicator | GERN | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 34.40 | 72.63 |
| Support Level | $1.22 | $3.72 |
| Resistance Level | $1.29 | N/A |
| Average True Range (ATR) | 0.06 | 0.88 |
| MACD | -0.00 | 0.24 |
| Stochastic Oscillator | 21.15 | 95.58 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.